Results 61 to 70 of about 18,821 (231)

Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The EMPIRE I study assessed the early (30 days) safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the commercially available ALLEGRA transcatheter aortic valve in patients with either severe native aortic stenosis or a degenerated surgical bioprosthesis.
José Antonio Baz, Claire B. Ren, Christof Burgdorf, Christian Frerker, Ignacio Cruz‐González, Joan Antoni Gómez, José Maria Hernândez, Pilar Jimenez, Ernest Spitzer, Pim Tonino, Pieter Vriesendorp, Nicolas van Mieghem, Samuel Copt, Anders Jönsson, Keith G. Oldroyd, Nicolas Doll   +15 more
wiley   +1 more source

ADP-Mediated Upregulation of Expression of CD62P on Human Platelets Is Critically Dependent on Co-Activation of P2Y1 and P2Y12 Receptors

Pharmaceuticals, 2020
This study probed the differential utilization of P2Y1 and P2Y12 receptors in mobilizing CD62P (P-selectin) from intracellular granules following activation of human platelets with adenosine 5′-diphosphate (ADP, 100 µmol·L−1) Platelet-rich plasma (PRP ...
Ronald Anderson, Annette J. Theron, Helen C. Steel, Jan G. Nel, Gregory R. Tintinger   +4 more
doaj   +1 more source

Role of Neuroimaging Before Coronary Angiography in Patients With Out‐of‐Hospital Cardiac Arrest

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Patients presenting following out‐of‐hospital cardiac arrest (OOHCA) often require emergency coronary angiography. Presentations can be associated with syncope or head‐trauma. Aims We investigated the impact and utility of pre‐coronary angiography CT‐Brain (CT‐B) in patients following OOHCA on clinical outcomes.
Edmond Wong, Kathryn Yu, Davide Tomassoni, Timothy Scully, Timothy Yeung, Jennifer Cooke, David Tong, Jaya Chandrasekhar, Jason Nogic   +8 more
wiley   +1 more source

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. [PDF]

, 2015
Antiplatelet therapy with P2Y12 receptor inhibitors has become the cornerstone of medical treatment in patients with acute coronary syndrome, after percutaneous coronary intervention and in secondary prevention of atherothrombotic events.
Siller-Matula, Jolanta, Kubica, Jacek, Kozinski, Marek, Aradi, Dániel, Winter, Max-Paul   +4 more
core   +1 more source

Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a Case Series

Cellular Physiology and Biochemistry, 2017
Background/Aims: Patients with acute coronary syndromes (ACS) presenting with cardiogenic shock (CS) are at particular risk for death and adverse cardiac events.
Michal Droppa, Oliver Borst, Dominik Rath, Karin Müller, Meinrad Gawaz, Deepak L. Bhatt, Tobia Geisler   +6 more
doaj   +1 more source

Ticagrelor Can Regulate the Ion Channel Characteristics of Superior Cervical Ganglion Neurons after Myocardial Infarction

Journal of Cardiovascular Development and Disease, 2023
Background: The superior cervical ganglion (SCG) plays a key role in cardiovascular diseases. The aim of this study was to determine the changes in the ion channel characteristics of the SCG following myocardial infarction (MI) and the role of ...
Lijun Cheng, Lin Yu, Xiaoping Zhan, Gary Tse, Tong Liu, Huaying Fu, Guangping Li   +6 more
doaj   +1 more source

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider, Sean R. McMahon, Dominick J. Angiolillo, Alexander C. Fanaroff, Homam Ibrahim, Patrick K. Hohl, Brett L. Wanamaker, Mark B. Effron, Peter M. DiBattiste, behalf of the investigators   +9 more
wiley   +1 more source

Structure of the human P2Y12 receptor in complex with an antithrombotic drug [PDF]

Nature, 2014
P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides. There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y1-like receptors and P2Y12-like receptors.
Kaihua, Zhang, Jin, Zhang, Zhan-Guo, Gao, Dandan, Zhang, Lan, Zhu, Gye Won, Han, Steven M, Moss, Silvia, Paoletta, Evgeny, Kiselev, Weizhen, Lu, Gustavo, Fenalti, Wenru, Zhang, Christa E, Müller, Huaiyu, Yang, Hualiang, Jiang, Vadim, Cherezov, Vsevolod, Katritch, Kenneth A, Jacobson, Raymond C, Stevens, Beili, Wu, Qiang, Zhao   +20 more
openaire   +2 more sources

The P2Y12 Receptor Antagonist Ticagrelor Reduces Lysosomal pH and Autofluorescence in Retinal Pigmented Epithelial Cells From the ABCA4-/- Mouse Model of Retinal Degeneration

Frontiers in Pharmacology, 2018
The accumulation of partially degraded lipid waste in lysosomal-related organelles may contribute to pathology in many aging diseases. The presence of these lipofuscin granules is particularly evident in the autofluorescent lysosome-associated organelles
Wennan Lu, Néstor M. Gómez, Jason C. Lim, Sonia Guha, Sonia Guha, Ann O’Brien-Jenkins, Erin E. Coffey, Keith E. Campagno, Stuart A. McCaughey, Alan M. Laties, Leif G. Carlsson, Claire H. Mitchell, Claire H. Mitchell, Claire H. Mitchell   +13 more
doaj   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source